A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
This study has been completed.
Information provided by:
First received: October 6, 2008
Last updated: November 30, 2009
Last verified: November 2009
This study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment. 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.
Drug: Phentermine and Topiramate
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase I, Open Label, Single-Dose Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment and In Healthy Control Subjects
Primary Outcome Measures:
- Pharmacokinetics [ Time Frame: 9 days ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||March 2009 (Final data collection date for primary outcome measure)
Experimental: Treatment A
Drug: Phentermine and Topiramate
Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
This study will look at the effect of a single does of study medication in three groups. Each group will have 6 - 8 subjects with similar levels of hepatic impairment. Group 1 will have normal hepatic function. Groups 2 and 3 will be made up of subjects with mild to moderate hepatic impairment. Subjects will have blood taken at specific intervals to measure study medication levels. Subject participation will last approximately 7 to 9 days.
|Ages Eligible for Study:
||18 Years to 65 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
A total of 18 to 24 subjects will be studied in 3 groups of 6-8 subjects per group. Group 1 will consist of 6-8 males or females with normal hepatic function, 18 to 65 years of age inclusive. Groups 2-3 will consist of 6-8 males or females per group with varying degree of stable hepatic impairment.
Any Subject meeting the following criteria must be excluded from the trial:
- Known history of clinically significant arrhythmias.
- Acute illness, especially any infection, within 2 weeks of dosing.
History or presence of:
- Alcoholism or drug abuse within the past 2 years.
- Hypersensitivity or idiosyncratic reaction to compounds related to the study drug or related compounds.
- Any History of Bipolar disorder or psychosis, history of psychiatric hospitalization, greater than one lifetime episode of major depression.
- Blood donation or significant blood loss within 56 days prior to Day 1.
- Plasma donation within 7 days prior to Day 1.
- Any subject who has participated in a previous clinical trial with VI-0521.
- Any subject who received an investigational drug within 30 days prior to dosing in this study.
- Any history of glaucoma, increased intraocular pressure, or medications to treat increased intraocular pressure.
- Serum creatinine > 1.5 for male subjects, and >1.4 for female subjects.
- History of kidney stones in the last 6 months
- Female subjects, who may be pregnant, or are lactating.
- Use of any drug that is known to have clinical significance in inhibiting or inducing liver enzymes involved in drug metabolism.
- Use of tobacco or nicotine products within last 6 months unless subject is hepatically-impaired.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00768209
|Clinical Pharmacology of Miami
|Miami, Florida, United States, 33014-3616 |
|Orlando Clinical Research Center
|Orlando, Florida, United States, 32809-3017 |
||Shiyin Yee, PhD
No publications provided
||Wesley Day, VP Clinical, Vivus, Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 6, 2008
||November 30, 2009
||United States: Food and Drug Administration
Keywords provided by VIVUS, Inc.:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 16, 2013
Digestive System Diseases
Central Nervous System Stimulants
Physiological Effects of Drugs
Central Nervous System Agents
Peripheral Nervous System Agents
Molecular Mechanisms of Pharmacological Action